Active monitoring for low-risk DCIS results in similar quality of life as standard treatment

Patients with low-risk ductal carcinoma in situ (DCIS) who underwent active monitoring reported comparable physical, emotional, and psychological outcomes to patients who received upfront treatment, according to results from the…

Continue ReadingActive monitoring for low-risk DCIS results in similar quality of life as standard treatment

PATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cancer

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first-line maintenance therapy…

Continue ReadingPATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cancer

COMET trial shows active monitoring is noninferior to standard treatment for low-risk DCIS

Among patients with hormone receptor (HR)-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS), those who underwent active monitoring had similar two-year invasive ipsilateral breast cancer recurrence rates as those who…

Continue ReadingCOMET trial shows active monitoring is noninferior to standard treatment for low-risk DCIS